Last reviewed 2026-04-20 · How we verify

Bradilan (NICOFURANOSE)

Phase 2 active Small molecule

Bradilan (generic name: NICOFURANOSE) is a nicofuranose drug. It is currently in Phase 2 development.

Bradilan works by interacting with a specific cellular target to produce a therapeutic effect.

Bradilan, also known as Nicofuranose, is a small molecule drug in the nicofuranose class. Its exact target and mechanism of action are unknown, but it is being developed for potential therapeutic applications. The commercial status of Bradilan is unclear, and it is not yet FDA-approved for any indications. Further research is needed to determine its efficacy and safety profile. As a result, key safety considerations and potential side effects are currently unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NICOFURANOSE
Drug class	nicofuranose
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your cells have locks on them, and Bradilan has a key that fits into those locks. When it binds to the lock, it triggers a series of events that ultimately lead to a desired outcome, such as reducing inflammation or improving cellular function. However, the exact details of how Bradilan interacts with its target are still not well understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bradilan CI brief — competitive landscape report
Bradilan updates RSS · CI watch RSS

Frequently asked questions about Bradilan

What is Bradilan?

Bradilan (NICOFURANOSE) is a nicofuranose drug.

How does Bradilan work?

Bradilan works by interacting with a specific cellular target to produce a therapeutic effect.

What is the generic name of Bradilan?

NICOFURANOSE is the generic (nonproprietary) name of Bradilan.

What drug class is Bradilan in?

Bradilan belongs to the nicofuranose class. See all nicofuranose drugs at /class/nicofuranose.

What development phase is Bradilan in?

Bradilan is in Phase 2.

Drug class: All nicofuranose drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing